Dachaigh › Astrocytoma › North Carolina
Sgrùdaidhean clionaigeach Astrocytoma ann an North Carolina
Tha 7 sgrùdaidhean airson Astrocytoma a’ lorg phàirtichean aig làraichean ann an North Carolina.
Bailtean ann an North Carolina
Teacsa sgrùdaidh oifigeil (Beurla)
Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
A’ fastadhSgrùdadh amharc
12 Months – 39 Years · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Wake Forest University Health Sciences, Winston-Salem
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Sult 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
A’ fastadhÌre 2
Aoisean 12 gu 39 · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Lùna 2026 · NCT05303519Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
A’ fastadhÌre 1 tràthFàilte do shaor-thoilich fhallain
Aoisean 1 gu 21 · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
A’ fastadhÌre 2
12 Months – 39 Years · Gach gnè · Air ùrachadh 29 Cèit 2026 · NCT05843253Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- Duke University, Durham
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Ògmh 2025 · NCT05879367Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.